Pages that link to "Q36938773"
Jump to navigation
Jump to search
The following pages link to Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera (Q36938773):
Displaying 50 items.
- Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib (Q26750696) (← links)
- The Role of Reactive Oxygen Species in Myelofibrosis and Related Neoplasms (Q26779929) (← links)
- New Therapeutic Approaches in Polycythemia Vera (Q26795677) (← links)
- Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management (Q26851894) (← links)
- Monitoring Minimal Residual Disease in the Myeloproliferative Neoplasms: Current Applications and Emerging Approaches (Q28076096) (← links)
- Ruxolitinib in the treatment of polycythemia vera: patient selection and special considerations (Q28078404) (← links)
- Refractory anemia with ring sideroblasts and RARS with thrombocytosis (Q28083238) (← links)
- Management of polycythaemia vera: a critical review of current data (Q31009757) (← links)
- Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera (Q33398180) (← links)
- Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib (Q33402522) (← links)
- Emerging drugs for myelofibrosis (Q33404574) (← links)
- A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea (Q33411637) (← links)
- Ruxolitinib versus standard therapy for the treatment of polycythemia vera. (Q33420037) (← links)
- 2016 WHO Clinical Molecular and Pathological Criteria for Classification and Staging of Myeloproliferative Neoplasms (MPN) Caused by MPN Driver Mutations in the JAK2, MPL and CALR Genes in the Context of New 2016 WHO Classification: Prognostic and T (Q33572605) (← links)
- Experience with ruxolitinib in the treatment of polycythaemia vera (Q33605624) (← links)
- Polycythemia Vera Management and Challenges in the Community Health Setting (Q33803036) (← links)
- Myeloproliferative Neoplasms: Molecular Pathophysiology, Essential Clinical Understanding, and Treatment Strategies (Q34158356) (← links)
- Targeting myeloproliferative neoplasms with JAK inhibitors (Q34159701) (← links)
- HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans (Q34162151) (← links)
- Annual Clinical Updates in Hematological Malignancies: A Continuing Medical Education Series: Polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk‐stratification, and management (Q34166859) (← links)
- Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms (Q34302770) (← links)
- Pharmacological management of essential thrombocythemia (Q34344384) (← links)
- Paediatric essential thrombocythaemia: clinical and molecular features, diagnosis and treatment (Q34370771) (← links)
- Investigational Janus kinase inhibitors. (Q34648724) (← links)
- The Ph-positive and Ph-negative myeloproliferative neoplasms: some topical pre-clinical and clinical issues (Q34750582) (← links)
- How I treat essential thrombocythemia (Q35132271) (← links)
- Immune derangements in patients with myelofibrosis: the role of Treg, Th17, and sIL2Rα. (Q35203067) (← links)
- Thrombocytosis: diagnostic evaluation, thrombotic risk stratification, and risk-based management strategies (Q35433259) (← links)
- Current and future treatment options for polycythemia vera (Q35572748) (← links)
- Emerging treatments for essential thrombocythemia (Q35683853) (← links)
- Mechanisms of thrombogenesis in polycythemia vera (Q35738656) (← links)
- The orally bioavailable MDM2 antagonist RG7112 and pegylated interferon α 2a target JAK2V617F-positive progenitor and stem cells (Q35743852) (← links)
- Decrease in JAK2 V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera (Q35944657) (← links)
- Differential Dynamics of CALR Mutant Allele Burden in Myeloproliferative Neoplasms during Interferon Alfa Treatment (Q36169641) (← links)
- Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera (Q36169783) (← links)
- Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b. (Q36311347) (← links)
- Experience with pegylated interferon α-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients (Q36366962) (← links)
- Allogeneic hematopoietic cell transplantation for advanced polycythemia vera and essential thrombocythemia (Q36404698) (← links)
- Sprouty proteins are negative regulators of interferon (IFN) signaling and IFN-inducible biological responses (Q36452049) (← links)
- JAK2 Allele Burden in the Myeloproliferative Neoplasms: Effects on Phenotype, Prognosis and Change with Treatment. (Q36612537) (← links)
- Update on JAK2 Inhibitors in Myeloproliferative Neoplasm (Q36612569) (← links)
- Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera (Q36814639) (← links)
- Novel and emerging therapies for the treatment of polycythemia vera (Q37069633) (← links)
- Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a (Q37083947) (← links)
- Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM090 (Q37250169) (← links)
- Changes in peripheral blood lymphocytes in polycythemia vera and essential thrombocythemia patients treated with pegylated-interferon alpha and correlation with JAK2V617F allelic burden (Q37286731) (← links)
- From leeches to personalized medicine: evolving concepts in the management of polycythemia vera (Q37555790) (← links)
- Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms. (Q37679175) (← links)
- Experimental therapeutics for patients with myeloproliferative neoplasias (Q37797983) (← links)
- Future Therapies for the Myeloproliferative Neoplasms (Q37809804) (← links)